Human proteomics: From the operating room to the lab and back
Human proteomics: From the operating room to the lab and back
Optimizing platforms for surgical specimen collection and deep human phenotyping was used to enhance protein biomarker identification using proteomic tools. A series of studies using human eye fluids has helped to diagnose inflammatory retinal disease, select personalized therapies, stage cancer, and point to new therapeutic strategies. These approaches can be broadly applied to human surgical disease.
Learning Objectives
- Learn workflow for human surgical specimen collection
- Learn human disease proteomics experimental design
- Learn future applications of human proteomics to disease diagnosis and treatment
Vinit Mahajan, MD, PhD
Vice Chair for Research, Director, Omics Lab, Molecular Surgery Program
Stanford University
Dr. Mahajan is a vitreoretinal surgeon and professor in the Department of Ophthalmology at Stanford University. He is the Vice Chair for Research and directs the Molecular Surgery Program and the NIH-funded Omics Laboratory that uses high-throughput methods in proteomics, genomics, and phenomics to identify molecules involved in eye disease. His research team discovered the first gene to cause non-syndromic uveitis and is now using protein crystallography to design therapeutic inhibitors for calpain-5. Mahajan and his team performed the first CRISPR gene editing therapy for eye disease in human stem cells. Using translational proteomics, Mahajan’s multidisciplinary team is developing new precision health approaches using molecular biomarkers to diagnose retinal disease, select personalized therapies, and decode the anatomic structures of the human eye.
Human proteomics: from the operating room to the lab and back
A presentation by Vinit Mahajan, MD, PhD
More webinars
WebinarEvaluation of precision and correlation for the latest proteomic platforms
The field of proteomics is rapidly advancing, enabling precise measurement of thousands of proteins, particularly those in higher abundance. This webcast will explore significant differences in precision within and across the latest large-scale proteomic platforms and their intercorrelations, based on blind duplicate split assays of the leading modified aptamer-based 11K and antibody proximity ligation-based 5K platforms. Each platform exhibits distinct strengths and limitations, requiring careful consideration prior to implementation in individual studies.
WebinarScaling Proteomics: Balancing Performance and Measuring Enough Proteins
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains? To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.
WebinarFrom discovery to clinical insights – the power of integrating proteomics and genomics data
The value of adding high-plex proteomics to existing genomics data and how proteogenomic approaches accelerate drug target discovery and repurposing. Watch this presentation given by Maik Pietzner, PhD, at ESHG 2024.